EGFR inhibitor Lapatinib and Gefitinib had higher IC50 in the low-risk group than that in the high-risk group (Figures 8A, B), suggesting EGFR inhibitors could be potential pharmacological therapies for patients with high-risk glioma. The gene discussed is EGFR; the disease is central nervous system cancer.